Skip to main content

Table 2 Positivity rate of Ancylostoma in two sets of dogs on St. Kitts

From: Ancylostoma in dogs in the Caribbean: a review and study from St. Kitts, West Indies

  Field Studya 2014 Clinic Dataa 2018–2019 P-valued
  N (%) Positive (%) P-valuec N (%) Positive (%) P-valuec
Age (months)
 < 6 4 (4.1) 1 (25.0) 0.3899 52 (22.4) 5 (9.6) 0.2924 0.0002
 6–12 17 (17.5) 10 (58.8) 27 (11.6) 5 (18.5)
 > 12 76 (78.4) 48 (63.2) 153 (65.9) 13 (8.5)
Sex
 Male 45 (46.4) 30 (66.7) 0.3741 108 (46.8) 12 (11.1) 0.7401 1.0
 Female 52 (53.6) 29 (55.8) 123 (53.2) 11 (8.9)
Anthelmintic useb
 Monthly 5 (5.2) 1 (20.0) 0.0299 121 (52.2) 6 (5.0) 0.0154 0.0001
 Other 35 (36.1) 18 (51.4) 36 (15.5) 4 (11.1)
 None 57 (58.8) 40 (70.2) 75 (32.3) 13 (17.3)
Total 97 59 (60.8)   232 23 (9.9)   0.0001
  1. aThe 2014 data represent dogs with limited veterinary care. Clinic data, January 2018–December 2019, represent dogs with greater veterinary care
  2. bMonthly defined as a Dirofilaria immitis preventative excluding Revolution® (selamectin). Other defined as an anthelmintic administered within the previous 6 months with activity against Ancylostoma. None indicates the owner had not administered any anthelmintic in the previous 6 months (2014 data) or there were no records of dispensing an anthelmintic (2018–2019 data)
  3. cBased on a chi-square or Fisher’s exact test
  4. dBased on a χ2 or Fisher’s exact test; comparison between the two study groups